Novavax Inc
Change company Symbol lookup
Select an option...
NVAX Novavax Inc
MRK Merck & Co Inc
HYT BlackRock Corporate High Yield Fund, Inc
FNMA Federal National Mortgage Association
CPKF Chesapeake Financial Shares Inc
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
Go

Health Care : Biotechnology | Mid Cap Value
Company profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Closing Price
$102.05
Day's Change
-4.99 (-4.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
108.20
Day's Low
100.37
Volume
(Average)
Volume:
2,708,264

10-day average volume:
2,557,587
2,708,264

AMD launches new chips for PCs

1:30 pm ET October 8, 2020 (MarketWatch)
Print

By Emily Bary

Chip maker says new Ryzen processors for desktops deliver a better gaming experience than prior-generation models

Advanced Micro Devices Inc. announced new desktop processors Thursday that the company said will deliver improvements in gaming performance.

AMD AMD (#phrase-company?ref=COMPANY%7CAMD;onlineSignificance=prominent) announced in a news release that the new PC chips in its Ryzen 5000 series offer a performance boost over prior-generation models, while the flagship Ryzen 9 5950X chip delivers what the company described as the "highest single-thread performance of any desktop gaming processor."

AMD's new "Zen 3" core architecture brings about a 19% "generational increase" in the number of instructions per cycle, AMD said, which marks the largest increase since the company introduced its Zen processors back in 2017.

"Zen 3 increases our lead in overall performance, it increases our lead in power efficiency, and also now, it delivers the best single-threaded performance, and gaming performance as well," Chief Executive Lisa Su said in an event announcing the new chips that was broadcast on YouTube.

The new CPUs are expected to be available Nov. 5. The Ryzen 9 5950X offers 16 cores, 32 threads, and 72MB of cache space, and it will sell for $799. The Ryzen 9 5900 has 12 cores, 24 threads, and 70MB of cache, for a price of $549. That model offers a 26% speed boost on average over the Risen 9 3900XT, based on tests done across 11 popular gaming titles.

AMD is also rolling out the Ryzen 7 5800X, with 8 cores, 16 threads, and 36MB of cache, as well as the Ryzen 6 5600X, with 6 cores, 12 threads, and 35MB of cache. Those will cost $499 and $299, respectively.

Opinion: Nvidia's deal for Arm could mean a real challenge to Intel and AMD, but is likely to face opposition (https://www.marketwatch.com/story/nvidias-deal-for-arm-could-mean-a-real-challenge-to-intel-and-amd-but-is-likely-to-face-opposition-2020-09-14)

AMD shares were near flat in Thursday's session, down from earlier gains. They've gained 62% in the past three months as the S&P 500 has risen 8.5%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 08, 2020 13:30 ET (17:30 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.